The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Size Is Forecasted For The Oral Antidiabetic Drugs Market By 2030 Based On Its 2026 Value?
The oral antidiabetic drugs market has demonstrated robust growth in recent years. It is projected to expand from $66.73 billion in 2025 to $71.42 billion in 2026, at a compound annual growth rate (CAGR) of 7.0%. The historical growth can be attributed to several factors, including the limited availability of oral antidiabetic drug classes, the reliance on conventional biguanides and sulfonylureas, the increasing incidence of type 2 diabetes, the expansion of hospital and pharmacy distribution networks, and a rising awareness concerning diabetes management.
The oral antidiabetic drugs market size is expected to undergo strong growth in the coming years. It is projected to expand to $92.64 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 6.7%. The anticipated growth during the forecast period can be attributed to factors such as the development of novel DPP-4 inhibitors and SGLT2 inhibitors, the expansion of combination therapies, increasing adoption of personalized medicine approaches, the growth of online pharmacy and telemedicine channels, and rising government initiatives for diabetes care. Major trends within the forecast period include the rising prevalence of type 2 diabetes, the increasing adoption of combination oral antidiabetic drugs, the expansion of online and retail pharmacy channels, a growing focus on personalized diabetes management, and enhanced awareness and education on diabetes care.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25854&type=smp
What Primary Factors Are Fueling The Expansion Of The Oral Antidiabetic Drugs Market?
The expanding prevalence of type 2 diabetes is anticipated to drive the expansion of the oral antidiabetic drugs market in the future. This condition is characterized by the body’s inability to effectively utilize insulin or an insufficient production of it, leading to elevated glucose levels. The escalating rates of type 2 diabetes are attributable to rising obesity, as surplus body fat contributes to insulin resistance and hindered glucose regulation. Oral antidiabetic medications aid in the management of type 2 diabetes through various mechanisms, such as boosting insulin sensitivity, stimulating insulin secretion, or curbing glucose synthesis and uptake, thereby ensuring stable blood sugar levels. As an illustration, the Office for Health Improvement and Disparities, a UK-based government agency, reported in March 2025 that the occurrence of type 2 diabetes among adults aged 17 and above in England increased to 7.0%, a rise from 6.8% recorded in March 2023. Consequently, the growing incidence of type 2 diabetes is propelling the growth of the oral antidiabetic drugs market.
Which Segment Divisions Form The Structure Of The Oral Antidiabetic Drugs Market?
The oral antidiabetic drugs market covered in this report is segmented –
1) By Drug Class: Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Sodium Glucose Transport Protein -2 Inhibitors, Sulfonylureas, Thiazolidinediones, Megalitinides, Alpha Glucosidase Inhibitors, Other Drug Classes
2) By Route Of Administration: Oral, Sublingual, Buccal
3) By Therapeutic Area: Type 2 Diabetes, Gestational Diabetes, Type 1 Diabetes
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Channels
5) By End User: Hospitals, Pharmact Store, Drug Store, Diabetes Treatment Centers, Other End Users
Subsegments:
1) By Biguanides: Metformin Hydrochloride, Metformin Extended Release, Combination Products
2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin
3) By Sodium Glucose Transport Protein-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin
4) By Sulfonylureas: Glipizide, Glyburide, Glimepiride, Chlorpropamide, Tolbutamide
5) By Thiazolidinediones: Pioglitazone, Rosiglitazone
6) By Meglitinides: Repaglinide, Nateglinide
7) By Alpha Glucosidase Inhibitors: Acarbose, Miglitol, Voglibose
8) By Other Drug Classes: Bromocriptine, Colesevelam
What Trends Are Driving Changes In The Oral Antidiabetic Drugs Market?
Major companies active within the oral antidiabetic drugs market are dedicating resources to clinical trials, aiming to develop increasingly effective and safer treatment options, diversify their product portfolios, and secure regulatory approvals for upcoming therapies. Clinical trials themselves are controlled research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of new medical treatments, drugs, or interventions. For example, in April 2025, Eli Lilly and Company, a US-based pharmaceutical company, unveiled Orforglipron. This once-daily oral small-molecule GLP-1 receptor agonist, which successfully completed a phase 3 trial, was specifically designed to simplify diabetes management. The goal of this oral therapy is to offer comparable efficacy and safety to existing injectable options while simultaneously boosting patient adherence. Clinical trial data showed that orforglipron lowered HbA1c (a key indicator of blood sugar control) by an average of 1.3% to 1.6% across various dosages over 40 weeks.
Who Are The Leading Firms Participating In The Oral Antidiabetic Drugs Market?
Major companies operating in the oral antidiabetic drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, C.H. Boehringer Sohn AG & Co. KG, Viatris Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Cipla Limited
Access The Complete Oral Antidiabetic Drugs Market Report:
https://www.thebusinessresearchcompany.com/report/oral-antidiabetic-drugs-global-market-report
Which Region Is The Dominant Market In The Oral Antidiabetic Drugs Market?
North America was the largest region in the oral antidiabetic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral antidiabetic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Oral Antidiabetic Drugs Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=25854&type=smp
Browse Through More Reports Similar to the Global Oral Antidiabetic Drugs Market 2026, By The Business Research Company
Antidiabetics Market Report 2026
https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report
Antidiabetics Market Report 2026
https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report
Antidiabetics Market Report 2026
https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model